Show/Hide Menu

MorphoSys's vision

MorphoSys is committed to develop exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry.

Events

09. Thu
March

Publication of Year-End 2016 Results

03. Wed
May

Publication of First Quarter Interim Statement 2017

17. Wed
May

Annual General Meeting 2017

Munich, Germany

Presentations

02/16/2017
LEERINK Partners 6th Annual Global Healthcare Conference
New York, USA
01/17/2017
Kepler Cheuvreux German Corporate Conference
Frankfurt/Main
01/12/2017
J.P. Morgan Healthcare Conference
San Francisco, USA
12/05/2016
MorphoSys Investor Event ASH 2016 (Dec. 5, 2016)
12/01/2016
dbAccess Pharmaceutical & Healthcare Corporate Day
London, UK

Media and investors

Anke Linnartz

Vice President, Head of Corporate Communications and IR

Phone: +49 89 89927 404

Fax: +49 89 89927 5404

Email Contact
LinkedIn-Profile

Alexandra Goller

Senior Manager Corporate Communications and Investor Relations

Phone: +49 89 89927 404

Fax: +49 89 89927 5404

Email Contact
LinkedIn-Profile

Jochen Orlowski

Associate Director Corporate Communications and Investor Relations

Phone: +49 89 89927 404

Fax: +49 89 89927 5404

Email Contact